Hestia Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.40 M
- Revenue Growth -31.34%
- Profit Growth 1.58%
- Ebitda -156.34%
- Net Worth 82.92%
- Total Assets 24.80%
About Hestia Pharma
Hestia Pharma Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 August 2010 and has a history of 14 years and six months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.40 M.
Edavalath Kumar, Theruvath Sharanya, Theke Ramesan, and One other member serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232KA2010PTC054892
- Company No.
054892
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Hestia Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Varikkol  | Director | 19-Aug-2010 | Current |
| Edavalath Kumar | Director | 21-Apr-2023 | Current |
| Theruvath Sharanya | Director | 21-Apr-2023 | Current |
| Theke Ramesan | Director | 05-Jul-2020 | Current |
Financial Performance of Hestia Pharma.
Hestia Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 31.34% decrease. The company also saw a slight improvement in profitability, with a 1.58% increase in profit. The company's net worth Soared by an impressive increase of 82.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hestia Pharma?
In 2019, Hestia Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.40 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Travancore : 0.14 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Aug 2013 | State Bank Of Travancore | ₹1.40 M | Open |
How Many Employees Work at Hestia Pharma?
Unlock and access historical data on people associated with Hestia Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hestia Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hestia Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
